ISPC
iSpecimen Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-69/100
Last price
1.15
▲ 0.10 (9.52%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.15
Prev close
1.05
Day high
1.10
Day low
1.03
Volume
102.64K
Market cap
$2.69M
P/E (TTM)
—
52W range
1.02 – 40.80
Day trading desk
Gap from prior close
+9.52%
Prior close 1.05
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
1.15 – 1.15
Position in range
—
—
ATR (14D)
0.09
7.39% of price
Prior day high
1.09
PDH
Prior day low
1.02
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 680.21K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-13.01%
-15.0%
1M
-30.52%
-31.7%
3M
-53.28%
-57.8%
6M
-81.42%
-99.6%
YTD
-89.71%
-104.0%
1Y
-97.65%
-114.1%
3Y
-99.78%
-182.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ISPC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$2.69M
Enterprise value$-1.48M
Revenue (TTM)$466.30K
Gross profit$-504.83K
EBITDA$-9.28M
Net income$-11.42M
EPS (TTM)$-52.98
Free cash flow$-5.58M
Total cash$4.41M
Total debt$240.90K
Book value / share$1.14
Shares outstanding2.52M
Float2.52M
Short % of float8.76%
Dividend yield0.00%
Beta (5Y)1.65
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.35
PEG ratio—
Price / sales—
Price / book0.94
EV / revenue-3.17
EV / EBITDA0.16
Gross margin-108.26%
Operating margin-897.05%
Profit margin0.00%
Return on equity-968.47%
Return on assets-87.69%
Debt / equity13.87
Current ratio0.82
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.93M | $9.29M | $9.93M | $10.40M | -79.2% |
| Operating revenue | $1.93M | $9.29M | $9.93M | $10.40M | -79.2% |
| Cost of revenue | $1.90M | $5.30M | $4.82M | $4.76M | -64.1% |
| Gross profit | $24.11K | $3.99M | $5.11M | $5.65M | -99.4% |
| Research & development | $2.16M | $3.53M | $3.57M | $2.66M | -38.8% |
| Selling, general & admin | $6.60M | $12.65M | $11.68M | $12.37M | -47.9% |
| Total operating expense | $9.00M | $16.72M | $16.28M | $15.83M | -46.1% |
| Operating income | -$8.98M | -$12.73M | -$11.17M | -$10.19M | +29.5% |
| Net interest income | -$6.17K | -$175.94K | $108.97K | -$69.62K | +96.5% |
| Pre-tax income | -$10.49M | -$12.50M | -$11.10M | -$10.25M | +16.1% |
| Net income | -$10.49M | -$12.50M | -$11.10M | -$10.25M | +16.1% |
| Net income to common | -$10.49M | -$12.50M | -$11.10M | -$10.25M | +16.1% |
| Basic EPS | -91.20 | -703.20 | -982.00 | -928.00 | +87.0% |
| Diluted EPS | -91.20 | -703.20 | -982.00 | -928.00 | +87.0% |
| EBIT | -$10.48M | -$12.28M | -$10.87M | -$10.01M | +14.7% |
| EBITDA | -$8.75M | -$9.98M | -$8.75M | -$8.80M | +12.4% |
| Basic shares | 115.06K | 17.77K | 11.30K | 11.05K | +547.5% |
| Diluted shares | 115.06K | 17.77K | 11.30K | 11.05K | +547.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.88M | $1.88M | $2.34M | $15.31M | — | +266.3% |
| Cash & short-term investments | $6.88M | $1.88M | $5.01M | $15.31M | — | +266.3% |
| Accounts receivable | $48.30K | $1.44M | $728.39K | $1.60M | — | -96.7% |
| Inventory | $0 | $45.11K | — | — | — | -100.0% |
| Total current assets | $6.95M | $3.59M | $8.24M | $19.68M | — | +93.8% |
| Property, plant & equipment | $294.70K | $421.54K | $321.64K | $410.54K | — | -30.1% |
| Goodwill & intangibles | $2.27M | $5.33M | $7.23M | $4.50M | — | -57.4% |
| Total assets | $9.53M | $9.35M | $15.82M | $24.62M | — | +1.9% |
| Total current liabilities | $6.23M | $5.77M | $6.05M | $4.28M | — | +8.0% |
| Long-term debt | — | — | — | — | $3.42M | — |
| Total debt | $268.80K | $312.17K | $196.24K | $185.85K | — | -13.9% |
| Total liabilities | $6.44M | $6.04M | $6.08M | $4.31M | — | +6.7% |
| Retained earnings | -$82.35M | -$71.86M | -$59.36M | -$48.27M | — | -14.6% |
| Shareholder equity | $3.09M | $3.31M | $9.74M | $20.31M | — | -6.7% |
| Working capital | $723.28K | -$2.18M | $2.19M | $15.39M | — | +133.1% |
| Net tangible assets | $818.21K | -$2.02M | $2.51M | $15.81M | — | +140.6% |
| Shares issued | 212.00K | 42.46K | 11.39K | 11.20K | — | +399.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$10.49M | -$12.50M | -$11.10M | -$10.25M | +16.1% |
| Depreciation & amortisation | $1.73M | $2.29M | $2.12M | $1.21M | -24.6% |
| Stock-based compensation | $21.27K | $249.68K | $459.67K | $678.61K | -91.5% |
| Change in working capital | $2.11M | -$502.67K | $2.59M | $2.35M | +520.5% |
| Operating cash flow | -$4.24M | -$8.26M | -$5.81M | -$5.82M | +48.7% |
| Capital expenditure | -$1.00M | -$709.83K | -$4.74M | -$3.19M | -40.9% |
| Investing cash flow | -$1.00M | $1.98M | -$7.23M | -$3.19M | -150.5% |
| Financing cash flow | $10.24M | $5.82M | $70.89K | -$3.42M | +76.0% |
| Free cash flow | -$5.24M | -$8.97M | -$10.55M | -$9.01M | +41.6% |
| End cash position | $6.88M | $1.88M | $2.34M | $15.31M | +266.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $151.94K | $156.01K | $51.76K | $106.59K | $713.13K | — | -2.6% |
| Operating revenue | $151.94K | $156.01K | $51.76K | $106.59K | $713.13K | — | -2.6% |
| Cost of revenue | $83.29K | $84.41K | $598.84K | $204.59K | $444.18K | — | -1.3% |
| Gross profit | $68.65K | $71.60K | -$547.08K | -$98.00K | $268.96K | — | -4.1% |
| Research & development | $290.23K | $247.55K | $527.03K | $551.10K | $536.31K | — | +17.2% |
| Selling, general & admin | $986.97K | $2.22M | $2.28M | $2.00M | $1.21M | — | -55.6% |
| Total operating expense | $1.43M | $2.61M | $2.14M | $2.73M | $2.09M | — | -45.1% |
| Operating income | -$1.36M | -$2.54M | -$2.69M | -$2.83M | -$1.82M | — | +46.3% |
| Net interest income | $270 | -$962 | -$848 | $2.36K | $10.02K | — | +128.1% |
| Pre-tax income | -$1.36M | -$2.28M | -$5.00M | -$2.78M | -$1.05M | — | +40.1% |
| Net income | -$1.36M | -$2.28M | -$5.00M | -$2.78M | -$1.05M | — | +40.1% |
| Net income to common | -$1.36M | -$2.28M | -$5.00M | -$2.78M | -$1.05M | — | +40.1% |
| Basic EPS | -0.98 | -6.66 | — | -19.20 | -16.78 | -28.55 | +85.3% |
| Diluted EPS | -0.98 | -6.66 | — | -19.20 | -16.78 | -28.55 | +85.3% |
| EBIT | -$1.36M | -$2.27M | -$5.00M | -$2.78M | -$1.05M | — | +40.1% |
| EBITDA | -$1.16M | -$2.14M | -$4.59M | -$2.32M | -$614.51K | — | +45.7% |
| Basic shares | 1.39M | 341.38K | — | 145.99K | 62.42K | 58.08K | +308.5% |
| Diluted shares | 1.39M | 341.38K | — | 145.99K | 62.42K | 58.08K | +308.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.41M | $2.82M | $6.88M | $2.78M | $588.77K | +56.6% |
| Cash & short-term investments | $4.41M | $2.82M | $6.88M | $2.78M | $588.77K | +56.6% |
| Accounts receivable | $21.26K | $132.85K | $48.30K | $120.93K | $372.47K | -84.0% |
| Inventory | — | — | $0 | — | — | — |
| Total current assets | $4.48M | $3.48M | $6.95M | $3.60M | $1.17M | +28.7% |
| Property, plant & equipment | $259.40K | $277.05K | $294.70K | $326.81K | $358.79K | -6.4% |
| Goodwill & intangibles | $2.64M | $2.84M | $2.27M | $5.06M | $4.50M | -7.0% |
| Total assets | $7.39M | $6.61M | $9.53M | $9.00M | $6.03M | +11.9% |
| Total current liabilities | $5.48M | $5.60M | $6.23M | $5.70M | $5.17M | -2.2% |
| Total debt | $240.90K | $254.99K | $268.80K | $281.44K | $287.88K | -5.5% |
| Total liabilities | $5.66M | $5.80M | $6.44M | $5.92M | $5.41M | -2.4% |
| Retained earnings | -$85.99M | -$84.63M | -$82.35M | -$77.35M | -$74.57M | -1.6% |
| Shareholder equity | $1.74M | $814.04K | $3.09M | $3.07M | $621.97K | +113.3% |
| Working capital | -$992.54K | -$2.12M | $723.28K | -$2.10M | -$4.01M | +53.1% |
| Net tangible assets | -$900.76K | -$2.02M | $818.21K | -$1.98M | -$3.88M | +55.5% |
| Shares issued | 1.52M | 741.60K | 212.00K | 244.31K | 62.46K | +105.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$1.36M | -$2.28M | -$5.00M | -$2.78M | -$1.05M | — | +40.1% |
| Depreciation & amortisation | $201.47K | $135.94K | $407.73K | $457.73K | $432.73K | — | +48.2% |
| Stock-based compensation | $153 | $1.03K | $1.76K | $1.80K | $1.80K | — | -85.1% |
| Change in working capital | $475.51K | -$962.44K | $1.31M | $289.04K | $513.94K | — | +149.4% |
| Operating cash flow | -$689.63K | -$3.36M | -$916.92K | -$2.04M | -$192.23K | — | +79.5% |
| Capital expenditure | — | -$700.00K | — | -$1.00M | — | — | — |
| Investing cash flow | $0 | -$700.00K | $0 | -$1.00M | -$454 | — | +100.0% |
| Share buybacks | — | — | — | $0 | $0 | $0 | — |
| Financing cash flow | — | — | $5.01M | $5.23M | -$1.10K | $0 | — |
| Free cash flow | -$689.63K | -$4.06M | -$916.92K | -$3.04M | -$192.69K | — | +83.0% |
| End cash position | $4.41M | $2.82M | $6.88M | $2.78M | $588.77K | — | +56.6% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2024 | -224.00 | -152.00 | +32.1% |
| Mar 2024 | -216.00 | -256.00 | -18.5% |
| Dec 2023 | -192.00 | -272.00 | -41.7% |
| Sep 2023 | -280.00 | -184.00 | +34.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions2.58%
Institutions holding8
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.17
-1.54% from price
SMA 20
1.28
-16.47% from price
SMA 50
1.66
-35.50% from price
SMA 100
2.23
-48.42% from price
SMA 200
5.97
-82.07% from price
EMA 12
1.19
-3.15% from price
EMA 26
1.36
-15.16% from price
EMA 50
1.69
-31.95% from price
RSI (14)
25.6
Oversold
MACD (12,26,9)
-0.17
Hist 0.00
ATR (14)
0.09
7.94% of price
Realised vol 30D
49.0%
Annualised
Bollinger upper
1.56
20, 2σ
Bollinger lower
1.00
20, 2σ
50 / 200 cross
Death
1.66 vs 5.97
Trend bias
Below 200
-82.07%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.84
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
49.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-97.6%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.09
7.94% of price
Beta (reported)
1.65
5Y monthly, from filing
Short interest
Shares short
220.72K
Prior 149.71K
Change vs prior
+47.4%
Shorts adding
% of float
8.76%
Normal
% of shares out
8.76%
Against total outstanding
Days to cover
0.1
Liquid
Float
2.52M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 22 | EF Hutton | MAINTAINED | — | Buy |
| Jan 4, 22 | Craig-Hallum | INITIATED | — | Buy |
| Nov 22, 21 | EF Hutton | MAINTAINED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:40
Split dateApr 28, 2026
SEC filings
Proxy Statements
DEF 14A · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-09-04
Corporate Changes & Voting Matters
8-K · 2026-08-31
Corporate Changes & Voting Matters
8-K · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-11
Offering Registrations
S-1/A · 2026-07-17
Corporate Changes & Voting Matters
8-K · 2026-07-14
Headlines
iSpecimen Supports Hospital Validation of New Chemistry Analyzer
TMX Newsfile · 8d ago
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
GlobeNewswire · 48d ago
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
TMX Newsfile · 48d ago
iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire · 61d ago
E.F. Hutton & Co. Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
GlobeNewswire · 61d ago
E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
GlobeNewswire · 61d ago
iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.